Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTAF-2: Perindopril for AF Recurrence Prevention in Hypertension
NCT00461903Phase 3Completed
- Sponsor
- Montréal Heart Institute
- Start
- Dec 2007
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perindopril in Atrial fibrillation (AFib), sponsored by Montréal Heart Institute. Primary endpoint: Time to first sustained recurrence of atrial fibrillation at 12 months. Started Dec 2007; status: completed.
02
Drugs
perindopril
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00461903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461903.